Ramucirumab use and potential risks of interstitial lung disease and pneumonitis: Analysis of individual case safety reports in VigiBase

被引：0

作者：

Alfadel, Nouf ^{[1
]}

Alharbi, Fawaz ^{[1
]}

机构：

[1] Saudi Food & Drug Author, Riyadh, Saudi Arabia

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

4797

引用

页码：467 / 467

页数：1

共 50 条

[41] Pre-existing interstitial lung disease as a risk factor for pneumonitis associated with ramucirumab and paclitaxel in patients with gastric cancer: The impact of usual interstitial pneumonia
Koyama, Nobuyuki
Katayanagi, Sou
Kawachi, Shigeyuki
PLOS ONE, 2018, 13 (06):
[42] Multiple drugsInterstitial lung disease/pneumonitis and lack of efficacy: 22 case reports
Reactions Weekly, 2025, 2045 (1) : 268 - 268
[43] Renal Safety Profile of EGFR Targeted Therapies: A Study from VigiBase(R) the WHO Global Database of Individual Case Safety Reports
Crosnier, Alexandre
Abbara, Chadi
Cellier, Morgane
Lagarce, Laurence
Babin, Marina
Bourneau-Martin, Delphine
Briet, Marie
CANCERS, 2021, 13 (23)
[44] Enfortumab-vedotinHyperglycaemia and interstitial lung disease: 2 case reports
Reactions Weekly, 2025, 2045 (1) : 156 - 156
[45] Multiple drugsFebrile neutropenia and interstitial lung disease: 2 case reports
Reactions Weekly, 2022, 1924 (1) : 297 - 297
[46] Docetaxel/pemetrexedAcute exacerbation of interstitial lung disease: 2 case reports
Reactions Weekly, 2019, 1740 (1) : 133 - 133
[47] PaclitaxelAnorexia, fatigue and exacerbation of interstitial lung disease: 2 case reports
Reactions Weekly, 2023, 1953 (1) : 332 - 332
[48] Docetaxel/nivolumab/ramucirumabPsoriasis and interstitial lung disease: 3 case reports
Reactions Weekly, 2020, 1810 (1) : 95 - 95
[49] OlaparibDrug-induced interstitial lung disease: 3 case reports
Reactions Weekly, 2023, 1972 (1) : 284 - 284
[50] Multiple drugsAcute exacerbation of interstitial lung disease: 6 case reports
Reactions Weekly, 2021, 1864 (1) : 245 - 245

← 1 2 3 4 5 →